Aromatase Inhibitors for Ovarian Stimulation in Patients with Breast Cancer

(E-pub Ahead of Print)

Author(s): Esteban Ferreiro, Belén López de Uralde, Rita Abreu, Juan A García-Velasco, Elkin Muñoz*.

Journal Name: Current Drug Targets

Become EABM
Become Reviewer

Abstract:

Background: Breast cancer is the most common malignancy diagnosed in women, and its treatment has a high probability of loss of fertility. Oocyte vitrification is the most commonly used technique to preserve fertility before starting oncological treatment. Aromatase inhibitors induce a hypoestrogenemia while promoting the release of gonadotropins and constitute an alternative drug for ovarian stimulation in patients with breast cancer.

Objective: In this mini-review, we update and describe the current status of aromatase inhibitor use in controlled ovarian stimulation for oocyte vitrification in patients with breast cancer.

Results: Aromatase inhibitors are commonly used in combination with gonadotropins for ovarian stimulation in patients with breast cancer who preserve their fertility through oocyte vitrification. They achieve similar ovarian responses as conventional ovarian stimulation protocols in regards to the number of oocytes, and no additional complications after their use have been reported. Furthermore, aromatase inhibitors seem to be safe not only for offspring, as no more congenital defects occur in newborns from pregnancies achieved after their use, but also for the patients, as no more malignancy recurrence or increased mortality was found in cohort studies.

Conclusion: Aromatase inhibitors are elective drugs for ovarian stimulation in patients with breast cancer who decide to preserve their fertility through oocyte vitrification.

Keywords: Aromatase inhibitors, Breast cancer, Ovarian stimulation, Fertility preservation, Hypoestrogenemia, safety

Rights & PermissionsPrintExport Cite as


Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1389450121666200220124607
Price: $95